Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Weighted Average) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4.63% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, up 4.63% year-over-year, with the annual reading at $15.5 million for FY2025, 4.63% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $15.5 million at Inhibrx Biosciences, roughly flat from $15.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $15.5 million in Q4 2025, with the low at $2.0 million in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 3 years is $12.5 million, with a median of $14.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 33.98% in 2024, then tumbled 85.34% in 2025.
  • Over 3 years, Shares Outstanding (Weighted Average) stood at $11.8 million in 2023, then increased by 25.62% to $14.8 million in 2024, then rose by 4.63% to $15.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $15.5 million, $15.5 million, and $15.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.